Have we finally identified an autoimmune demyelinating disease?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

9 citing papers in PubMed.

1. Pathology-supported genetic testing as a method for disability prevention in multiple sclerosis (MS). Part I. Targeting a metabolic model rather than autoimmunity.Metabolic brain disease · 2021
   Review
2. Anti-Kir4.1 Antibodies in Multiple Sclerosis: Specificity and Pathogenicity.International journal of molecular sciences · 2020
   Review
3. Identification of an iron-responsive subtype in two children diagnosed with relapsing-remitting multiple sclerosis using whole exome sequencing.Molecular genetics and metabolism reports · 2019
   Article
4. The fat mass and obesity-associated FTO rs9939609 polymorphism is associated with elevated homocysteine levels in patients with multiple sclerosis screened for vascular risk factors.Metabolic brain disease · 2014
   Article
5. The conundrum of iron in multiple sclerosis--time for an individualised approach.Metabolic brain disease · 2012
   Review
6. Differentiation of neuromyelitis optica from multiple sclerosis on spinal magnetic resonance imaging.International journal of MS care · 2012
   Article
7. Is multiple sclerosis an autoimmune disease?Autoimmune diseases · 2012
   Article
8. Evidence for the role of B cells and immunoglobulins in the pathogenesis of multiple sclerosis.Neurology research international · 2011
   Article
9. Quo vadis multiple sclerosis?Inflammopharmacology · 2010
   Article

Corrections and comments

• Comment on
  Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo.2009
• Comment on
  Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica.2009

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as